This study looks at two medicines, sonrotoclax and zanubrutinib, for people with a type of blood cancer called Chronic Lymphocytic Leukemia (CLL). CLL is when the body makes too many abnormal white blood cells. Sonrotoclax is a test drug that blocks a protein helping cancer cells grow, called B-cell lymphoma-2 (Bcl-2). Zanubrutinib is an approved medicine that blocks another protein called Bruton's tyrosine kinase (BTK), controlling cancer cells. The study is to see if combining both drugs works better than just using zanubrutinib alone.

In this study, about 87 people will be randomly chosen to get either the combination of both medicines or just zanubrutinib. The study will last about five years and will take place in various locations around the world.

• Participants need to be 18 years or older with untreated CLL.
• It’s important to have certain health levels, like good liver and kidney function.
• Women must agree to use birth control during and a bit after the study.